Review of NICE Technology Appraisal Guidance No.219; Everolimus for the second-line treatment of metastatic renal cell carcinoma

The Institute was proposing that the guidance should be transferred to the ‘static guidance list’.

Responses received from stakeholders during the consultation suggested that this may not be the most appropriate course of action and that an update of TA219 may be required.

After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided that TA219 should be updated alongside other treatments for renal cell carcinoma after failure of prior systemic treatment, including sunitinib and sorafenib (part review of TA178) and other new treatments such as axitinib.  This review will be conducted through the Multiple Technology Appraisal (MTA) process.

December 2014

Attachments

Appendix A - GE decision paper - November 2014